DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication
Artículo científico (JournalArticle)
Rapamycin negatively impacts insulin signaling, glucose uptake and uncoupling protein-1 in brown adipocytes
New onset diabetes after transplantation (NODAT) is a metabolic disorder that affects 40% of patients on immunosuppressive agent (IA) treatment, such as rapamycin (also known as sirolimus). IAs negatively modulate insulin action in peripheral tissues including skeletal muscle, liver and white fat. However, the effects of IAs on insulin sensitivity and thermogenesis in brown adipose tissue (BAT) have not been investigated. We have analyzed the impact of rapamycin on insulin signaling, thermogenic gene-expression and mitochondrial respiration in BAT. Treatment of brown adipocytes with rapamycin for 16 h significantly decreased insulin receptor substrate 1 (IRS1) protein expression and insulin-mediated protein kinase B (Akt) phosphorylation. Consequently, both insulin-induced glucose transporter 4 (GLUT4) translocation to the plasma membrane and glucose uptake were decreased. Early activation of the N-terminal Janus activated kinase (JNK) was also observed, thereby increasing IRS1 Ser 307 phosphorylation. These effects of rapamycin on insulin signaling in brown adipocytes were partly prevented by a JNK inhibitor. In vivo treatment of rats with rapamycin for three weeks abolished insulin-mediated Akt phosphorylation in BAT. Rapamycin also inhibited norepinephrine (NE)-induced lipolysis, the expression of peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) and uncoupling protein (UCP)-1 in brown adipocytes. Importantly, basal mitochondrial respiration, proton leak and maximal respiratory capacity were significantly decreased in brown adipocytes treated with rapamycin. In conclusion, we demonstrate, for the first time the important role of brown adipocytes as target cells of rapamycin, suggesting that insulin resistance in BAT might play a major role in NODAT development., This work was supported by Ministerio de Economía y Competitividad: (SAF2015-65267-R to AMV, SAF2012-32491 to MJO, SAF2013-45887-R to LH, and SAF2014-52223-C2-1-R to DS) that were cofunded by the Fondos Europeos de Desarrollo Regional de la Unión Europea [FEDER], Spain, Instituto de Salud Carlos III (FIS PI15-00448 to SC and INFLAMES PIE14/00045 to AMV), Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERdem, ISCIII, Spain) to AMV, Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBERobn-Grant CB06/03/0001) to DS and S2010/BMD-2423 (Comunidad de Madrid, Spain) to AMV and MJO and S2010/BMD-2402 to SC and 2014SGR465 (Generalitat de Catalunya, Spain) to DS. CdM was supported by the Albert Reynold Grant travel fellowship from the European Foundation for the Study of Diabetes. EC and FR were funded by FEDER through the Operational Programme Competitiveness Factors - COMPETE and by FCT - Foundation for Science and TechnologyPTDC/SAU-OSM/104124/2008 and strategic project UID/NEU/04539/2013., Peer Reviewed
Project:
MINECO / Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016 SAF2014-52223-C2-1-R
,
MINECO / Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016 SAF2013-45887-R
,
MINECO / Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016 SAF2015-65267-R
View at: http://hdl.handle.net/10261/150937